成人肝脏再移植:阿根廷单一中心23年经验的适应症和结果分析。

IF 0.3 Q4 TRANSPLANTATION
R Bruballa, D Sanchez Thomas, E de Santl'banes, M Ciardullo, J Mattera, J Pekolj, M de Santibanes, V Ardiles
{"title":"成人肝脏再移植:阿根廷单一中心23年经验的适应症和结果分析。","authors":"R Bruballa,&nbsp;D Sanchez Thomas,&nbsp;E de Santl'banes,&nbsp;M Ciardullo,&nbsp;J Mattera,&nbsp;J Pekolj,&nbsp;M de Santibanes,&nbsp;V Ardiles","doi":"","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Liver re-transplantation (re-LT) represents the only treatment for patients with irreversible graft failure.</p><p><strong>Objective: </strong>The aim of the current study was to describe the outcomes of both, patient and graft, after re- LT, at a high-volume referral center.</p><p><strong>Methods: </strong>Our population consisted of patients, with liver disease, who underwent re-LT in our institution between January 1996 and December 2019.</p><p><strong>Results: </strong>49 patients met the inclusion criteria. The patient's overall survival (OS) for the first year was 85% (Confidence Intervals (CI) 71-92) and 70% at five years (CI 53-82). In our population, three (6.12%) patients presented loss of graft and were included again in the transplant list; of these, one agreed to a new transplant while the remaining two died. This gave us graft survival results similar to those obtained for the re-LT patient; 85% at one year (CI 71-92) and 70% at 5 years (CI 53-82).</p><p><strong>Conclusion: </strong>Our study shows that re-LT is a valid and safe treatment for both early graft dysfunction and for transplanted patients who again present end-stage liver disease, showing a satisfactory long-term evolution, with parameters comparable to primary transplantation.</p>","PeriodicalId":14242,"journal":{"name":"International Journal of Organ Transplantation Medicine","volume":null,"pages":null},"PeriodicalIF":0.3000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10460530/pdf/ijotm-13-30.pdf","citationCount":"0","resultStr":"{\"title\":\"Liver Re-transplantation in Adults: Indications and Outcomes Analysis of a 23-year Experience in a Single Center in Argentina.\",\"authors\":\"R Bruballa,&nbsp;D Sanchez Thomas,&nbsp;E de Santl'banes,&nbsp;M Ciardullo,&nbsp;J Mattera,&nbsp;J Pekolj,&nbsp;M de Santibanes,&nbsp;V Ardiles\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Liver re-transplantation (re-LT) represents the only treatment for patients with irreversible graft failure.</p><p><strong>Objective: </strong>The aim of the current study was to describe the outcomes of both, patient and graft, after re- LT, at a high-volume referral center.</p><p><strong>Methods: </strong>Our population consisted of patients, with liver disease, who underwent re-LT in our institution between January 1996 and December 2019.</p><p><strong>Results: </strong>49 patients met the inclusion criteria. The patient's overall survival (OS) for the first year was 85% (Confidence Intervals (CI) 71-92) and 70% at five years (CI 53-82). In our population, three (6.12%) patients presented loss of graft and were included again in the transplant list; of these, one agreed to a new transplant while the remaining two died. This gave us graft survival results similar to those obtained for the re-LT patient; 85% at one year (CI 71-92) and 70% at 5 years (CI 53-82).</p><p><strong>Conclusion: </strong>Our study shows that re-LT is a valid and safe treatment for both early graft dysfunction and for transplanted patients who again present end-stage liver disease, showing a satisfactory long-term evolution, with parameters comparable to primary transplantation.</p>\",\"PeriodicalId\":14242,\"journal\":{\"name\":\"International Journal of Organ Transplantation Medicine\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.3000,\"publicationDate\":\"2022-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10460530/pdf/ijotm-13-30.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Journal of Organ Transplantation Medicine\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"TRANSPLANTATION\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Organ Transplantation Medicine","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"TRANSPLANTATION","Score":null,"Total":0}
引用次数: 0

摘要

背景:肝再移植(re-LT)是移植不可逆衰竭患者的唯一治疗方法。目的:当前研究的目的是描述患者和移植物在大容量转诊中心再肝移植后的结果。方法:我们的人群包括1996年1月至2019年12月期间在我们机构接受再肝移植的肝病患者。结果:49例患者符合纳入标准。患者第一年的总生存率(OS)为85%(置信区间(CI) 71-92), 5年生存率为70% (CI 53-82)。在我们的人群中,3例(6.12%)患者出现移植物丢失并再次被列入移植名单;其中一人同意接受新的移植手术,其余两人死亡。这给我们带来了与再移植肝移植患者相似的移植物存活结果;1年85% (CI 71-92), 5年70% (CI 53-82)。结论:我们的研究表明,对于早期移植物功能障碍和再次出现终末期肝病的移植患者,re-LT是一种有效且安全的治疗方法,显示出令人满意的长期进展,其参数与初次移植相当。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Liver Re-transplantation in Adults: Indications and Outcomes Analysis of a 23-year Experience in a Single Center in Argentina.

Liver Re-transplantation in Adults: Indications and Outcomes Analysis of a 23-year Experience in a Single Center in Argentina.

Background: Liver re-transplantation (re-LT) represents the only treatment for patients with irreversible graft failure.

Objective: The aim of the current study was to describe the outcomes of both, patient and graft, after re- LT, at a high-volume referral center.

Methods: Our population consisted of patients, with liver disease, who underwent re-LT in our institution between January 1996 and December 2019.

Results: 49 patients met the inclusion criteria. The patient's overall survival (OS) for the first year was 85% (Confidence Intervals (CI) 71-92) and 70% at five years (CI 53-82). In our population, three (6.12%) patients presented loss of graft and were included again in the transplant list; of these, one agreed to a new transplant while the remaining two died. This gave us graft survival results similar to those obtained for the re-LT patient; 85% at one year (CI 71-92) and 70% at 5 years (CI 53-82).

Conclusion: Our study shows that re-LT is a valid and safe treatment for both early graft dysfunction and for transplanted patients who again present end-stage liver disease, showing a satisfactory long-term evolution, with parameters comparable to primary transplantation.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
1.60
自引率
0.00%
发文量
0
审稿时长
12 weeks
期刊介绍: The International Journal of Organ Transplantation Medicine (IJOTM) is a quarterly peer-reviewed English-language journal that publishes high-quality basic sciences and clinical research on transplantation. The scope of the journal includes organ and tissue donation, procurement and preservation; surgical techniques, innovations, and novelties in all aspects of transplantation; genomics and immunobiology; immunosuppressive drugs and pharmacology relevant to transplantation; graft survival and prevention of graft dysfunction and failure; clinical trials and population analyses in the field of transplantation; transplant complications; cell and tissue transplantation; infection; post-transplant malignancies; sociological and ethical issues and xenotransplantation.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信